Company profile
Profusa, Inc. Common Stock
NASDAQ: PFSA · Healthcare · Medical - Devices
#1042 of 1,418 Healthcare companies by revenue
EA Score
9DFH 9DQ 8GM —SS 15
v0.1 · 55/100 weight · provisional
↑ market scale, Piotroski F · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$35.8M
Employees
2
as of 2026-08-28
Market cap
$3.2M
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$100.0k$100.0k2025
Net income-$35.8M-$35.8M2025
Operating income-$27.7M-$27.7M2025
Total assets$3.8M$3.8M2025
Liabilities$30.4M$30.4M2025
Equity-$26.7M-$26.7M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Profusa, Inc. Common Stock’s revenue?
Profusa, Inc. Common Stock booked $100.0k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -35823.0% net margin.
Peers · Healthcare
BioMark Diagnostics Inc.——Finch Therapeutics Group, Inc.——Meridian Holdings, Inc.——Therapeutic Solutions International, Inc.——Allied Corp.——Actinium Pharmaceuticals, Inc.28DNeighbors
Alameda →Key facts
CEOJack E. Stover
SectorHealthcare
IndustryMedical - Devices
HeadquartersEmeryVille, CA
ExchangeNASDAQ: PFSA
Employees2
IPO date2025-07-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.